JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Home・Aandelen Lijst・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Gesloten

1.72 -2.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.71

Max

1.8

Belangrijke statistieken
By Trading Economics
Inkomsten	13M -43M
Winstmarge	-2,190.837
Werknemers	171
EBITDA	17M -42M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+48.89% upside

Dividenden
By Dow Jones
Volgende Winsten	6 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3.7M 101M
Vorige openingsprijs	3.99
Vorige sluitingsprijs	1.72

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.43 / 1.6 Steun & Weerstand

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 okt 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 okt 2025, 23:25 UTC

Winsten

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 okt 2025, 23:18 UTC

Winsten

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 okt 2025, 22:20 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 okt 2025, 22:13 UTC

Winsten

Wal-Mart de Mexico Net Profit Falls in 3Q

28 okt 2025, 21:38 UTC

Winsten

Correction to Visa Sales Jump Article

28 okt 2025, 21:17 UTC

Winsten

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 okt 2025, 21:07 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- Update

28 okt 2025, 21:02 UTC

Winsten

Mondelez Tempers Outlook as Costs Rise

28 okt 2025, 23:51 UTC

Marktinformatie

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 okt 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 okt 2025, 23:02 UTC

Winsten

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 okt 2025, 23:01 UTC

Winsten

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 okt 2025, 22:46 UTC

Winsten

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 okt 2025, 22:45 UTC

Winsten

SK Hynix 3Q Net KRW12.6T >000660.SE

28 okt 2025, 22:44 UTC

Winsten

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 okt 2025, 22:43 UTC

Winsten

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 okt 2025, 22:42 UTC

Winsten

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 okt 2025, 22:20 UTC

Winsten

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 okt 2025, 22:02 UTC

Winsten

Review & Preview: Earnings Extravaganza -- Barrons.com

28 okt 2025, 21:42 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

28 okt 2025, 21:42 UTC

Marktinformatie

Winsten

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 okt 2025, 21:20 UTC

Winsten

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 okt 2025, 21:19 UTC

Winsten

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 okt 2025, 21:18 UTC

Winsten

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Koersdoel

By TipRanks

48.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.68 USD 48.89%

Hoogste 4 USD

Laagste 1.7 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pliant Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Pliant Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.